Erbitux and Avastin Aren’t Cost Effective, NICE Finds
This article was originally published in The Pink Sheet Daily
Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.
You may also be interested in...
India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
Roche's offer of lump-sum payments to the NHS fails to sway NICE in its second draft evaluation of Avastin for the indication, but because it is not yet a final determination, stakeholders will have an opportunity to weigh in.